Calidi Biotherapeutics Inc. (CLDI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
4475 EXECUTIVE DRIVE SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 1,949,000 | 93,892 | 1,062,653 | |||
| Cash and cash equivalents | 1,949,000 | 93,892 | 1,062,653 | |||
| Restricted cash and investments | ||||||
| Receivables | 870 | |||||
| Prepaid expense | 306,909 | 420,908 | ||||
| Other undisclosed current assets | 2,354,000 | |||||
| Total current assets: | 4,303,000 | 401,671 | 1,483,561 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 4,073,000 | |||||
| Prepaid expense | 280,944 | |||||
| Derivative instruments and hedges | 230,000 | |||||
| Asset, held-in-trust | 42,453,107 | 230,004,784 | ||||
| Other noncurrent assets | 143,000 | |||||
| Other undisclosed noncurrent assets | 1,270,000 | |||||
| Total noncurrent assets: | 5,716,000 | 42,453,107 | 230,285,728 | |||
| TOTAL ASSETS: | 10,019,000 | 42,854,778 | 231,769,289 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 388,000 | 3,270,694 | 410,985 | |||
| Accounts payable | 51,074 | 63,839 | ||||
| Accrued liabilities | 388,000 | 3,219,620 | 347,146 | |||
| Debt | 888,000 | |||||
| Deferred compensation liability | 1,600,000 | |||||
| Derivative instruments and hedges, liabilities | 32,865 | |||||
| Due to related parties | ✕ | ✕ | 1,224,635 | |||
| Other undisclosed current liabilities | 7,356,000 | 7,719 | ||||
| Total current liabilities: | 10,232,000 | 4,535,913 | 410,985 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 2,276,000 | |||||
| Long-term debt, excluding current maturities | 2,060,000 | |||||
| Finance lease, liability | 216,000 | |||||
| Liabilities, other than long-term debt | 4,537,000 | 745,000 | 7,469,150 | |||
| Other liabilities | 1,500,000 | |||||
| Operating lease, liability | 3,037,000 | |||||
| Derivative instruments and hedges, liabilities | 745,000 | 7,469,150 | ||||
| Other undisclosed noncurrent liabilities | 1,209,000 | 326,234 | 8,571,184 | |||
| Total noncurrent liabilities: | 8,022,000 | 1,071,234 | 16,040,334 | |||
| Total liabilities: | 18,254,000 | 5,607,147 | 16,451,319 | |||
| Temporary equity, carrying amount | 42,453,107 | 230,004,784 | ||||
| Equity | ||||||
| Equity, attributable to parent, including: | (8,235,000) | (5,205,476) | (14,686,814) | |||
| Common stock | 4,000 | |||||
| Additional paid in capital | 91,380,000 | |||||
| Accumulated other comprehensive loss | (47,000) | |||||
| Accumulated deficit | (99,572,000) | (5,206,051) | (14,687,389) | |||
| Other undisclosed equity, attributable to parent | 575 | 575 | ||||
| Equity, attributable to noncontrolling interest | ||||||
| Total equity: | (8,235,000) | (5,205,476) | (14,686,814) | |||
| TOTAL LIABILITIES AND EQUITY: | 10,019,000 | 42,854,778 | 231,769,289 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Operating expenses | (28,992,000) | (4,669,524) | |||
| Operating loss: | (28,992,000) | (4,669,524) | |||
| Nonoperating income (expense) | (208,000) | 8,546,701 | |||
| Other nonoperating expense | (51,000) | ||||
| Interest and debt expense | (1,100,000) | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (30,300,000) | 3,877,177 | |||
| Other undisclosed income from continuing operations before income taxes | 1,100,000 | ||||
| Income (loss) from continuing operations before income taxes: | (29,200,000) | 3,877,177 | |||
| Income tax expense | (16,000) | (346,987) | |||
| Net income (loss): | (29,216,000) | 3,530,190 | |||
| Net income attributable to noncontrolling interest | |||||
| Net income (loss) attributable to parent: | (29,216,000) | 3,530,190 | |||
| Preferred stock dividends and other adjustments | 2,458,852 | ||||
| Other undisclosed net loss available to common stockholders, basic | (4,917,704) | ||||
| Net income (loss) available to common stockholders, diluted: | (29,216,000) | 1,071,338 | |||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net income (loss): | (29,216,000) | 3,530,190 | |||
| Other undisclosed comprehensive loss | |||||
| Comprehensive income (loss): | (29,216,000) | 3,530,190 | |||
| Comprehensive income, net of tax, attributable to noncontrolling interest | |||||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (33,000) | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (29,249,000) | 3,530,190 | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.